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Delivery of genes that are larger than the wild-type 
adeno-associated virus (AAV) 4,681 nucleotide genome 
is inefficient using AAV vectors. We previously demon-
strated in vitro that concurrent proteasome inhibitor 
(PI) treatment improves transduction by AAV vectors 
 encoding oversized transgenes. In this study, an AAV 
vector with a 5.6 kilobase (kb) factor VIII expression cas-
sette was used to test the effect of an US Food and Drug 
 Administration–approved PI (bortezomib) treatment con-
current with vector delivery in vivo. Intrahepatic vector 
delivery resulted in factor VIII expression that persisted 
for >1 year in hemophilia mice. Single-dose bortezomib 
given with AAV2 or AAV8 factor VIII vector enhanced 
expression on average ~600 and ~300%, respectively. 
Moreover, co administration of AAV8.canineFVIII (1 × 
1013 vg/kg) and bortezomib in hemophilia A dogs (n = 
4) resulted in normalization of the whole blood clotting 
time (WBCT) and 90% reduction in hemorrhages for >32 
months compared to untreated hemophilia A dogs (n = 3) 
or dogs administered vector alone (n = 3). Demonstration 
of long-term phenotypic correction of hemophilia A dogs 
with combination adjuvant bortezomib and AAV vector 
expressing the oversized transgene establishes preclinical 
studies that support testing in humans and provides a 
working paradigm to facilitate a significant expansion of 
therapeutic targets for human gene therapy.
Received 11 February 2010; accepted 14 July 2010; published online  
10 August 2010. doi:10.1038/mt.2010.170
IntroductIon
The use of adeno-associated virus (AAV) vectors for correction of 
many clinically relevant congenital deficiencies has been hampered 
by the relatively limited packaging capacity imposed by the small 
size of the wild-type AAV genome (4,681 nt) and inefficient AAV 
vector delivery of genes that are larger than the wild-type (wt) 
AAV genome. AAV vectors for delivery of larger genomes (based 
on expression cassettes up to and exceeding 6.0 kb) have been 
produced; however, these vectors are inefficient, and multiple 
investigators have characterized their limitations.1–6 Strategies to 
improve the expression of large transgenes using AAV vectors 
include splitting large genomes for co-delivery using >1 AAV vec-
tor, or exploiting head-to-tail concatemer formation.5,7,8 Although 
these approaches fundamentally solve current packaging limita-
tions of AAV, they create other disadvantages. Cells have to be 
infected with numerous virus particles to increase the probability 
of transduction, and the system is reliant upon the efficiency of 
homologous recombination. Using deleted transgenes that retain 
therapeutic potential9 and optimizing expression cassettes with 
minimal transcriptional regulatory elements,5,10 when possible, 
have emerged as alternative solutions.
An understanding of the steps that follow receptor-mediated 
internalization of AAV into target cells is emerging, including mech-
anisms of endocytic processing and nuclear trafficking.3,11,12 These 
studies demonstrate that the majority of viral capsids do not appear 
to deliver their genome to the nucleus, and the current hypothesis 
suggests that AAV capsids are cleared from the cell by either of two 
major pathways for degrading cellular proteins, via the lysosome 
or the proteasome. In order for proteins to be degraded by the 
proteasome, they must first be conjugated to ubiquitin by specific 
cellular ligases. Previous research has  demonstrated  in vitro that 
AAV capsids can be ubiquitinated, but it is still unclear whether 
ubiquitination marks capsids for proteasomal degradation or acts 
as a trafficking signal. Proteasome inhibitors (PIs) are known to 
increase capsid ubiquitination and significantly enhance infection 
efficiency in a cell-type and serotype-specific manner. Although 
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the exact mechanism of enhancement remains unknown, it has 
been postulated that PIs do one or more of the following activi-
ties: block degradation of capsids in the cytoplasm, increase traf-
ficking efficiency, block degradation of capsids in the nucleus, or 
indirectly improve genome stability; recent studies demonstrate 
PIs may impact processing after uncoating (R. Jude Samulski, 
unpublished results). In vivo, PIs affect other cellular functions, 
e.g., immune processing.13–15 Among the available PIs, bortezomib 
(also called PS-341 or Velcade) is the only one approved for clini-
cal use. Bortezomib inhibits proteasome activity by forming a 
covalent bond with the active site threonine in the 20S core of the 
26S proteasome particle and inhibits the chymotryptic activity of 
the proteasome. Bortezomib has become especially important in 
the treatment of multiple myeloma, either as single-agent therapy 
or in combination with other drugs, including the corticosteroid 
dexamethasone.16
Hemophilia A, a genetic disorder caused by the deficient 
activity of the large coagulation protein factor VIII, has attracted 
significant attention as a target condition for gene therapy.17 Three 
human clinical trials of factor VIII gene therapy have failed to 
achieve persistent phenotypic correction. These trials utilized 
ex vivo fibroblast transduction, retrovirus vector, or gutted ade-
novirus vector for FVIII gene delivery.17 Previously Sarkar et al. 
reported that expression of a 5.6 kilobase (kb) coagulation fac-
tor VIII gene expression cassette delivered to the liver by serotype 
AAV8 vector was possible in mice and dogs, but the efficiency of 
infection was extremely low (~1 infectious particle: 40,000 total 
vector particles)6 and limiting with respect to vector production, 
dose required for correction,6,18 and the potential to translate to 
human clinical application. The potential for factor VIII expres-
sion as well as the inefficiency of the large transgene vector having 
been established by that study, we chose to examine the same vec-
tor and similar transduction conditions in the presence or absence 
of PI at the time of vector delivery. The phenotypic improvements 
demonstrated in this report, and additional incremental inno-
vations in factor VIII expression shown in subsequent efforts of 
others,5,18–21 emphasize that strategies to overcome the inefficient 
delivery of large transgenes using AAV could have significant 
clinical implications.
We have previously demonstrated that a variety of AAV 
serotype (1–6) vectors can be used to deliver large transgene 
expression cassettes and effectively transduce cells,3 albeit with 
an efficiency that is about one log lower than vectors produced 
using genomes of wtAAV size (<4.7 kb). Recently, three studies 
have characterized in greater detail the limitations of packag-
ing large genomes in AAV capsids (e.g., vectors produced from 
oversize genomes have lower particle number, lower transduction 
efficiency, and inefficient expression in vivo).22–24 These studies 
postulated complementation of incomplete genomes as a means 
to obtain protein expression.25 Using in vitro cell culture studies, 
we determined that PI treatment concurrent with AAV delivery 
improves transduction by AAV vectors that have been generated 
with larger genomes to a greater extent than AAV generated using 
the wt-size genome, allowing them to overcome to some degree 
the inherent inefficiency of large transgene vectors.3 Although the 
mechanism continues to be investigated, based on these in vitro 
observations, we propose this limiting aspect of oversized AAV 
vector transduction can be overcome pharmacologically in vivo by 
specifically using combination drug/vector therapy. In this report, 
we describe the details of combination therapy that utilizes limited 
exposure to bortezomib, a drug with well-defined preclinical and 
clinical toxicity and efficacy profile, to improve AAV-mediated 
expression of a large factor VIII transgene, achieving correction 
of hemophilia A mouse and canine models with follow-up of >2 
years.
results
PI bortezomib dose in vivo
The primary objective of these studies was to validate combina-
tion therapy using a clinically utilized PI and AAV transgene 
vectors in small and large animal disease models. PIs have been 
reported to increase rAAV vector transduction in vitro and 
in vivo by several mechanisms.3,11,12,26–28 Although we had previ-
ously studied several PIs in tissue culture,3,27 we wished to exam-
ine bortezomib (also known as PS-341 or Velcade), as this is the 
only PI currently approved for human clinical use. Bortezomib, 
like most chemotherapy agents, is dosed based on body surface 
area. For all large animal studies, we used the US Food and Drug 
Administration–approved dose of 1.3 mg/m2 (see http://www.
accessdata.fda.gov/drugsatfda_docs/label/2008/021602s015lbl.
pdf). This dose extrapolates to ~0.5–1.0 mg/kg of body weight for 
C57Bl/6 hemophilic mice weighing 25–30 g. Preclinical toxicity 
data have established a safe dose for frequent recurrent therapy 
of 0.5 mg per kilogram of body weight in mice;29 in these studies, 
mice receiving 1.0 mg/kg twice a week for 4 weeks experienced 
changes in weight, activity, and level of consciousness. We inde-
pendently established that mice given a single dose of 0.5 mg/
kg without AAV vector tolerated the PIs without apparent side 
effect or change in behavior or hematologic parameters (data 
not shown). Therefore, bortezomib was given at 0.5 mg/kg by a 
single portal vein injection coadministered with the AAV vectors 
in all mice studies, and this total dose used in mice is roughly 
equivalent to the total dose/kg body weight used in dog studies 
described below.
PI effect on AAV serotypes carrying wild-type size 
factor IX expression cassette in hemophilia B mice
Our previous in vitro studies suggest that proteasomal processes 
limit large transgene expression more than expression from vec-
tors delivering wtAAV size genomes. To evaluate this hypothesis, 
we tested the effect of combination therapy using bortezomib 
on AAV-mediated in vivo correction of hemophilic animals. We 
first used a vector carrying a genome approximately the same size 
as wild-type AAV for the correction of the hemophilia B mouse 
model. An AAV vector carrying a human factor IX expression 
cassette driven by the CMV enhancer/chicken β-actin promoter, 
described previously,30 was infused via the portal vein to hemo-
philia B mice with or without a single dose of bortezomib at 
the time of the vector delivery. As shown in Figure 1a, ssAAV2.
FIX-treated mice averaged 2.4% factor IX activity over 20 weeks 
of observation. Bortezomib treatment resulted in an average 
expression of 4.3% factor IX over the same period, equivalent to 
an 83% increase in factor IX expressed. Liver-directed factor IX 
expression was more efficient using AAV8 than AAV2, and mice 
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receiving vector alone expressed on average 40% factor IX activity 
over 20 weeks. Factor IX expression over 20 weeks was modestly 
augmented in mice receiving the single dose of bortezomib coad-
ministered with the AAV8 vector, averaging ~24% higher factor 
IX activity (Figure 1b).
PI effect on AAV serotypes expressing larger than 
wild-type size cFVIII expression cassette  
in hemophilia A mice
Having determined that coadministration of bortezomib with 
AAV vector carrying wt size factor IX transgene cassette results 
in increase (although modest) of both AAV serotypes 2 and 8 
transduction in the factor IX–deficient mouse model, we next 
focused on the effect of combination therapy using a large trans-
gene (FVIII) cassette in hemophilia A mice of the same genetic 
background (C57Bl/6). The factor VIII cDNA (~7.1 kb) contains 
a large B domain (~2.7 kb) that does not contribute to blood 
clotting; once the majority of sequence coding for the B domain 
is removed, the cFVIII cDNA sequence of 4.5 kb can be incor-
porated in AAV vectors. Nevertheless, the addition of promoter 
and other required transcriptional regulatory elements to these 
vectors results in an oversized AAV expression cassette of 5.6 kb. 
AAV2 and AAV8 vectors were generated using the 5.6 kb FVIII 
expression plasmid. Virus was characterized for total particle 
number by qPCR, virion integrity by electron microscopy, capsid 
ratio by silver stain, and DNA genome size by alkaline gel elec-
trophoresis (data not shown). For multiple production runs of 
vectors used for both mouse and canine studies, all these vector 
parameters were consistent with our previous published stud-
ies3 and those of others.6,22–24 For FVIII studies, the PIs MG-132 
(also called Z-LLL) and bortezomib were chosen so that we 
could compare the most effective PI used in our previous report3 
(MG-132) with the clinically approved agent, bortezomib. Both 
MG-132 and bortezomib led to increased FVIII transgene expres-
sion compared to mice receiving vector alone (Figure 1c,d). As 
shown in Figure 1c, FVIII activity was undetectable until week 
8 after AAV2 vector alone, whereas factor VIII was detectable 
at week 2 in mice receiving coadministration of MG-132 and 
at week 1 in mice that received bortezomib. Factor VIII expres-
sion was increased on average >150% by MG-132 and >550% by 
bortezomib.
In contrast to the delayed onset of expression observed in mice 
receiving AAV2 vector without PI, mice receiving the AAV8 vec-
tor alone (Figure 1d) had canine FVIII detectable at the earliest 
examination at week 1 after transduction. In these mice, canine 
factor VIII peaked at 8 weeks, then began to decrease. Although 
slightly increased factor VIII expression was observed in the 
first month after AAV8 with the coadministration of MG-132, 
the improvement of factor VIII expression was not significant or 
persistent, as was observed using bortezomib. Bortezomib coad-
ministration improved initial and sustained canine factor VIII 
expression. On average, factor VIII expression was 259% higher 
in mice receiving the single dose of bortezomib when compared 
to mice receiving AAV8.cFVIII vector alone. Analysis of liver 
alanine aminotransferase and aspartate aminotransferase, and 
complete blood counts did not show any evidence of hepatic 
or hematologic toxicity in any mice receiving vector alone or in 
combination with bortezomib. To facilitate comparison of the PI 
effect upon vectors generated from wtAAV-sized factor IX trans-
gene and oversized factor VIII transgene, the same time points 
are graphed in Figure 1a,b (factor IX) and Figure 1c,d (factor 
VIII). Bortezomib treatment was associated with a proportion-
ately greater augmentation of the oversize transgene expression 
than that of the smaller transgene. This result provides in vivo 
corroboration of our in vitro studies using chloramphenicol 
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Figure 1 effect of proteasome inhibitor combination therapy with AAV2 and AAV8 vectors for the correction of factor IX–deficient and factor 
VIII–deficient mice. Hemophilic mice received 3 × 1010 vector genomes/mouse of single AAV2 or AAV8 vectors with or without proteasome inhibitor 
(0.5 mg/kg body weight) by portal vein injection. (a,b) Percent of normal human factor IX activity in FIX−/− mice following AAV2 (a) or AAV8 (b) 
with or without bortezomib. (c,d) Percent of normal canine factor VIII activity (Coatest assay) in FVIII−/− mice following AAV2 (c) or AAV8 (d) in the 
presence of proteasome inhibitors MG-132 and bortezomib. Data are presented as mean ± SD. *Bortemozib or MG-132 versus AAV-cFVIII control, P < 
0.05. #Bortemozib versus MG-132, P < 0.05, n = 3–4/group in a; n = 5–6/group in b; n = 5/group in c; n = 6/group in d. Statistics was performed by 
analysis of variance on SigmaStat software.
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PI increases nuclear accumulation of genomes in vivo
PIs have been reported to increase rAAV vector transduction 
in vitro and in vivo by several mechanisms.3,11,12,26,27 Recently, we 
described a study wherein rAAV2 virions enter the nucleus intact, 
are sequestered in the nucleolus in stable form, and can be mobi-
lized from the nucleolus to nucleoplasmic sites likely permitting 
uncoating and subsequent gene expression or genome degrada-
tion. By examining these processes in the presence of PIs, we have 
refined our understanding of AAV2 trafficking dynamics and have 
identified cellular parameters that mobilize virions in the nucleus 
that significantly influence AAV infection. To evaluate trafficking 
dynamics in vivo, hemophilia A and B mice were next treated with 
combination therapy of PI, and either factor VIII or factor IX vec-
tor, respectively; the abundance of vector sequences in the cyto-
plasm and nuclear compartment were compared. Two weeks after 
vector administration with or without bortezomib, total liver cell 
cytoplasmic and nuclear fractions from AAV8.FVIII- or AAV8.
FIX-treated mice were purified and examined to determine the 
intracellular location of vector genomes. The ratio of genomes 
persisting in the nucleus rather than cytoplasm was increased by 
the single dose of bortezomib, supporting a role for inhibition 
of the proteasome pathway in promoting nuclear translocation 
(Table 1). This effect was demonstrated for both the oversized 
transgene (factor VIII) vector as well as for the wild-type size (fac-
tor IX) vector. These results, consistent with our in vitro studies, 
suggest a pathway that may divert vector genomes from cytoplasm 
to nuclear structures for subsequent steps in vector uncoating and/
or genome complementation as suggested by recent reports.22–25 
However, additional mechanism(s) likely exist to account for the 
augmented expression of oversized transgene vectors.
effect of dexamethasone upon ectopic AAV vector 
expression during liver-directed gene therapy
Bortezomib and dexamethasone are commonly used together in 
clinical oncology therapies. Compared with bortezomib  therapy 
alone, the combination of dexamethasone and bortezomib has 
increased efficacy, as has the addition of dexamethasone in the set-
ting of incomplete clinical response to bortezomib monotherapy.31–34 
To determine whether a similar cooperative action between these 
agents might enhance vector transduction by oversized transgene 
cassettes, we evaluated outcome of vector transduction in multi-
drug combination therapy. For example, in previous studies, we 
had examined various additional pharmacologic agents in an effort 
to decrease the uptake of AAV vectors expressing reporter gene at 
ectopic sites during liver-directed gene therapy (Supplementary 
Materials and Methods). During these early studies, we observed 
a trend to decrease ectopic vector scatter when dexamethasone 
was coadministered with vector. This was reflected in lower gene 
expression and lower genome persistence in several organs; for 
example, mean expression of marker gene was decreased 10–30 
times in heart, spleen, and pancreas (Supplementary Table S1 and 
data not shown). The degree of interanimal variation in off-target 
expression in the absence of dexamethasone was large, so that the 
trend of the dexamethasone effect was not statistically significant. 
Based on the clinical use of dexamethasone with bortezomib, and 
results above, we chose to treat an additional group of AAV8.
cFVIII/bortezomib mice simultaneously with a single dose of the 
corticosteroid dexamethasone and examine the effect upon persis-
tent transgene expression (see below).
long-term observation of pharmacologic 
enhancement of AAV.cFVIII expression in FVIII 
knockout mice
Having established the potential of bortezomib to enhance fac-
tor VIII expression, additional mice were treated with AAV2 and 
AAV8 vectors to determine the duration of bortezomib enhance-
ment. Circulating factor VIII activity in mice receiving AAV2 
alone was first detectable at 8 weeks, and fluctuated around the 
lower limit of detection of this assay (~1% activity = 0.01 IU/ml) 
throughout 1 year of observation. (Figure 2) However, coadmin-
istration of bortezomib resulted in detectable factor VIII activity 
at week 1 in most mice, which peaked at week 8 (0.11 ± 0.06 IU/
ml) and was maintained at >3% for a year. Expression of cFVIII 
from the AAV8 vector peaked at week 8 (0.51 ± 0.38 IU/ml) before 
gradually decreasing to a plateau ~10% of normal human factor 
VIII activity that was maintained to week 52 (the final observation, 
0.10 ± 0.019 IU/ml). In contrast, mice treated with AAV8.cFVIII 
and the single dose of bortezomib exceeded even at the first time 
point (week 1) the peak value of the vector-only group, and main-
tained cFVIII activity of >50% normal throughout 1 year of obser-
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Figure 2 Persistent adjuvant effect using single-dose bortezomib 
upon AAV2- and AAV8-mediated cFVIII expression in hemophilia A 
mice. FVIII−/− mice were injected with AAV2 or AAV8 expressing cFVIII 
at the dose of 3 × 1010 gc/mouse, without proteasome inhibitor or with 
bortezomib (0.5 mg/kg body weight) or bortezomib plus dexametha-
sone (0.2 mg/animal, equivalent to 8 mg/kg body weight) by portal vein 
injection. Citrated plasma was collected at defined time points and FVIII 
activity determined by Coatest assay. Data are presented as mean ± SD 
% normal canine FVIII activity. *AAV8.cFVIII + bortezomib (with or with-
out dexamethasone) versus AAV8.cFVIII vector alone, P < 0.05. #AAV2.
cFVIII + bortezomib versus AAV2.cFVIII vector alone, P < 0.05.
table 1 Proteasome inhibitor increases nuclear accumulation of 
genomes in vivo
treatment cytoplasm nucleus ratio n/c
AAV8-FIX 6.27 ± 1.47 3.21 ± 1.1 0.55 ± 0.25
AAV8-FIX+bortezomib 0.58 ± 0.43 13.2 ± 1.95 22.8 ± 27.3*
AAV8-cFVIII 4.46 ± 0.7 5.52 ± 0.96 1.23 ± 0.9
AAV8-cFVIII+bortezomib 1.2 ± 0.91 9.08 ± 2.61 7.57 ± 3.62*
Abbreviations: cFVIII, canine factor VIII; N/C, nuclear/cytoplasm.
Data are represented as mean ± SEM.
*P < 0.05.
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in Figure 2. In these studies, the overall pattern of  expression in 
bortezomib-treated mice was similar with and without the addi-
tion of dexamethasone.
development of canine FVIII–neutralizing antibodies 
in FVIII knockout mice
As described in the original report using this canine factor 
VIII expression construct,6 it is expected when treating factor 
VIII knockout mice that inhibitory antibodies against the fac-
tor VIII transgene may arise, given the cross-species origin of the 
protein. In our experience and in published reports,35 even one 
intravenous exposure to 1.0 unit human FVIII protein may lead 
to antibody formation in this strain of mice. Anti-cFVIII inhibitor 
antibody formation was largely avoided in the earlier study when 
mice were pretreated with cyclophosphamide as well as hemo-
static support with 1.2 U recombinant human FVIII for surgery.6 
As shown in Table 2, some mice in each of our treatment groups 
did develop FVIII-neutralizing antibodies at various times 2–20 
weeks after vector exposure, despite cyclophosphamide dosing 
performed per the schedule outlined by Sarkar et al.6 Inhibitor 
titers were near the lower limits of detection in the few AAV2.
cFVIII-treated mice that developed antibodies, and the signifi-
cance of these borderline titers is unclear. As previously reported 
by Jiang et al.,19 inhibitors developed more frequently following 
AAV8.cFVIII than with AAV2.cFVIII, being seen in 6/10 mice 
receiving AAV8.cFVIII without PI. Coadministration of borte-
zomib appeared to decrease the incidence of inhibitor formation 
in animals treated with the AAV8 serotype vector (5/15 mice, 
33.3%). The combination of corticosteroid and bortezomib was 
associated with the lowest rate of inhibitor formation (20% of 
AAV8.cFVIII/bortezomib/dexa methasone mice versus 60% of 
vector-only mice), suggesting potential benefit from this combi-
nation therapy.36
Phenotypic improvement of hemophilia A dogs given 
bortezomib concurrently with AAV vector
One primary object of this study was to validate combination ther-
apy using bortezomib for AAV enhancement of oversized trans-
gene in large animal model to better substantiate potential use in 
human. Using the identical AAV-cFVIII vector cassette used in 
the hemophilia A mouse studies, we next determined whether PI 
augmentation of the expression of large transgenes translates to 
the canine hemophilia A model. As a preliminary safety study, 
two hemostatically normal dogs were treated with a course of 
four doses of bortezomib using a treatment schedule typical for 
use in human oncology applications (1.3 mg/m2 twice a week 
for 2 weeks). The dogs developed no clinical symptoms, blood 
 chemistry, or cell count abnormalities (data not shown). Next, as 
shown in Table 3, a total of seven hemophilia A dogs were treated 
with AAV8.cFVIII with follow-up of at least 10 months (longest 
follow-up = 32 months). Three hemophilia A pups received a lim-
iting dose of 1 × 1013 vg/kg AAV8.cFVIII (AAV8) via the portal 
vein. Four hemophilia A pups received the same AAV therapy and 
received a single i.v. dose of the PI bortezomib at the clinically 
approved dose of (1.3 mg/m2). The vector and PI were well tol-
erated. Specifically, no liver transaminase elevations, neurologic 
symptoms, or changes in hematologic parameters occurred, and 
there was no development of factor VIII–neutralizing antibodies 
(FVIII inhibitors).
Correction of plasma clotting potential was quantified using 
a factor VIII–specific two-stage chromogenic factor VIII activ-
ity assay (Coatest) and the whole blood clotting time (WBCT). 
Peak factor VIII activity levels were achieved between days 7 and 
21 after vector delivery. Peak factor activities ranged from 0.5 to 
1.0 mIU/ml in two dogs receiving the AAV8.FVIII vector alone 
and was undetectable in the third dog. The factor VIII activity 
ranged from 2.2 to 3.8 mIU/ml in dogs receiving bortezomib with 
vector delivery; FVIII activity was not detected in one male dog 
that received vector alone and another female dog that received 
vector + bortezomib but without dexamethasone (Table 3). By 
the second month after vector delivery, only dogs that received 
bortezomib (± dexamethasone) maintained factor VIII activity 
above 1%, which the manufacturer defines as the level of sensitiv-
ity of the Coatest. To continue to allow relative comparisons of 
plasma clotting potential between the groups, all subsequent test-
ing used the WBCT, as this assay detects the clotting potential of 
much lower factor concentrations. The WBCT in hemostatically 
normal dogs is 6–10 minutes; the WBCT in untreated hemophilia 
A dogs is >20 minutes. Examining the potential effect of combina-
tion therapy at the earliest time point, the mean WBCT at 1 week 
after delivery of AAV8 alone was >16 minutes, as compared to 
8.8 minutes in dogs receiving bortezomib + AAV8 (Figure 3 and 
Table 3). 
Remarkably, the effect of the single dose of bortezomib was evi-
dent for months. Examining correction during the first 10 months 
following vector delivery (the minimum amount of follow-up that 
is available for all seven dogs), the two male dogs receiving AAV8 
alone had only 4 of a total of 40 (10%) individual WBCT mea-
surements in the normal range; males getting bortezomib + AAV8 
had 33 of 44 (75%) individual WBCT assays completely normal-
ized during the same period of observation. At longest follow-up 
(>11 months for all dogs), the male that received bortezomib + 
dexamethasone concurrent with AAV8 delivery was the only 
dog that maintained activity detectable in the chromogenic fac-
tor VIII activity assay (1.7–3.8 IU/ml at 33 months after vector). 
Liver transduction using AAV2 and AAV8 gene10,37 therapy vectors 
has been reported previously to be less efficient in females than in 
males. Female dogs receiving bortezomib + AAV8 had 12 of 40 
(30%) individual WBCT measurements corrected into the normal 
range over 10 months of follow-up; a female getting vector without 
PI had only 1 of 20 (5%) of WBCT values in the normal range.
table 2 Anti-cFVIII inhibitor development after AAV2 and AAV8  
treatment in FV1114 mice
Animals with inhibitor/total 
animals





AAV2-cFVIII 1/5 8 0.4–0.5 BIU
AAV2-cFVIII+bortezomib 2/6 4 and 8 0.4–1.2 BIU
AAV8-cFVIII 6/10 8–20 1.2–10.4 BIU
AAV8-cFVIII+bortezomib 5/15 2–20 1.0–13.2 BIU
AAV8-
cFVIII+bortezomib+Dex
2/10 6 and 20 0.5–2.4 BIU
Abbreviations: BIU, Bethesda units; cFVIII, canine factor VIII; Dex, Dexamethasone.
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Importantly, the combination therapy augmentation of plasma 
clotting potential translated directly into correction of the bleed-
ing phenotype (Table 3). This strain of hemophilia A dogs typi-
cally experiences bleeds about six times/year. Three age-matched 
untreated hemophilic dogs from the same colony bled 10, 10, and 
13 times each during 22 months’ observation concurrent with this 
study, resulting in a monthly bleeding rate of 0.50 ± 0.08 hemor-
rhages/month. The dogs receiving AAV8.FVIII vector alone had 
a mean bleeding frequency of 0.80 ± 0.26 bleeds/month, not sig-
nificantly different from untreated hemophilic dogs (P = 0.23). 
Dogs that received bortezomib with vector had a mean of 0.07 ± 
0.08 hemorrhages/month, which was a striking improvement 
compared to matched, untreated hemophilic dogs (P < 0.001) and 
vector-only treated dogs (P < 0.003). The original treatment group 
(n = 4) have now been followed for >32 months. Bortezomib + 
AAV8.cFVIII combination therapy dogs have had one and two 
spontaneous bleeds, respectively. During the same period, the 
dogs that received only vector had 12 and 16 bleeds before each 
experiencing a fatal hemorrhage at 16 and 25 months after vector 
treatment, respectively.
dIscussIon
Correction of hemophilia A through gene therapy remains an elu-
sive goal of modern medicine. Strategies using AAV vectors are 
attractive, but expression of factor VIII has thus far been ineffi-
cient, in part, because the factor VIII cDNA exceeds the packaging 
capacity of wt AAV. We have previously demonstrated that AAV 
vectors carrying oversize transgene cassettes transduce cells less 
efficiently.3 More importantly, this inefficiency can be overcome 
by the use of pharmacologic agents such as PIs.3 Based on these 
observations, we hypothesized that concurrent administration of 
the PI bortezomib with an AAV vector may have an adjuvant effect 
to facilitate persistent correction of diseases requiring expression 
of a large transgene. Here, we demonstrate that the expression of 
an oversized factor VIII cDNA delivered by AAV can be enhanced 
several fold in hemophilic mice and dogs. The enhanced expres-
sion was demonstrated using two different serotype AAV vectors. 
The effect persisted in vivo without further proteasome treatment 
(>1 year in hemophilic mice and >2-1/2 years in hemophilic 
dogs). Most importantly, in the hemophilia A dogs, the single-
dose PI therapy safely augmented a limiting AAV vector dose, 
which did not protect against hemorrhagic complications of the 
hemophilic phenotype in the absence of drug. As a result, only the 
dogs receiving bortezomib “combination therapy” demonstrated 
persistent protection from the chronic recurrent and lethal bleed-
ing complications of severe factor VIII deficiency.
overcoming AAV barriers
Understanding the cellular pathways that facilitate this nonpatho-
genic DNA virus to carry out successful infection has been instru-
mental in AAV vector development. For example, a number of 
groups11,38–40 have illustrated that drugs/chemicals such as bafilo-
mycin A, brefeldin A, and MG-132 augment rAAV transduction 
by acting at the level of endosome acidification, early-to-late endo-
some transition, and proteasome activity, respectively. The ability 
of PIs such as MG-132 and LLnL to increase vector transduction 
has provided further support to the notion that proteasomes in the 
cytoplasm act as barriers to AAV infection. These barriers have 
been characterized in detail both in vitro and in vivo, and inves-
tigations of working models for mode of action are ongoing. For 
example, Duan et al.12 described a tenfold increase in the propor-
tion of hepatocytes expressing AAV2 alkaline phosphatase trans-
gene after administration of PIs LLnL or Z-LLL supporting the 
hypothesis that viral capsid ubiquitination and subsequent pro-
teasomal processing place limitation on AAV transduction. This 
study and subsequent studies from Engelhardt and others have 
confirmed the influence of the ubiquitin-proteasome system, also 
demonstrating this system affected additional AAV serotypes (e.g., 
AAV5), but that the relative importance of this system differed 
between specific tissues.11,12,26,39 Additional insight into the relative 
importance of capsid ubiquitination as a limitation to AAV gene 
delivery comes from a series of studies from Srivastava et al.41,42 
Pursuing the concept that phosphorylation of the AAV capsid 
(e.g., by EGFR-PTK) is critical for subsequent ubiquitination, site-
directed mutagenesis of surface-exposed tyrosines on the AAV 
capsid was performed to remove potential sites of phosphoryla-
tion. The tyrosine mutant AAV capsids were relatively resistant to 
proteasome-mediated degradation and demonstrated increased 
expression in in vitro and in vivo experiments when compared to 
tyrosine-phosphorylated AAV. These and other models are being 
actively pursued to better understand barriers to AAV transduc-
tion imposed by the ubiquitin/proteasome system.
Impact of PIs on AAV oversized transgene expression
In this study, we aimed to advance these insights to preclini-
cal models using combination therapy with drugs having well-
characterized toxicity and efficacy profiles (e.g., PI bortezomib 
and corticosteroid dexamethasone) that would justify testing in 
human gene therapy trials. The current study confirms, in relevant 
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Figure 3 Persistent correction of hemophilia phenotype by adjuvant 
proteasome inhibitor with liver-directed AAV8-mediated cFVIII gene 
therapy in hemophilia A dogs. (a) Whole blood clotting time (WBCT) 
in two male and one female hemophilia A dogs treated with vector only 
and no bortezomib. (b) WBCT in two male and two female hemophilia 
A dogs treated with coadministration of a single dose of i.v. bortezomib 
at the time of AAV vector administration. Normal range of 6–10 minutes 
for hemostatically normal dogs is indicated by the shaded region. All 
hemophilic dogs had baseline WBCT >20 minutes.
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animal disease models, our previous in vitro observation that PIs 
overcome, in part, the inherent inefficiency of expressing large 
therapeutic transgenes from AAV. Our data strongly support the 
use of bortezomib with oversized AAV transgene cassettes such 
as FVIII. Although bortezomib is commonly given in combina-
tion with the corticosteroid dexamethasone, we did not observe 
in mice significant synergy in regards to enhancing hepatic gene 
expression when compared to bortezomib alone (Figure 2). 
Nevertheless, there may be additive effects upon antigen presen-
tation and immunologic tolerance that justify combining these 
drugs in gene transfer applications, as the combination led to the 
lowest inhibitor antibody formation in the inhibitor-prone mice. 
(Table 2) Additionally, although the numbers of dogs treated 
do not allow statements regarding the significance of different 
treatment effects, greatest persistence of factor VIII activity was 
observed, for both the dogs of male and female gender, in the dogs 
that received the combined adjuvant drugs dexamethasone and 
bortizomib with AAV (Greg and Marjorie in Table 3).
In addition to the rescuing of oversized AAV transgene cas-
sette transduction with the use of adjuvant bortezomib therapy, a 
more modest (less than twofold) augmentation was observed for 
wild-type size AAVFIX vectors (Figure 1). It is not clear why we 
see a more dramatic impact in vivo upon transduction of oversized 
genomes. In our previous in vitro study, AAV1 vectors encapsidat-
ing transgene cassettes of 4.7, 5.3, and 6.0 kb were used to trans-
duce HeLa cells, and coadministration of the PI LLnL increased 
expression 1.1-, 2.2-, and 5.7-fold respectively, when compared to 
the level of expression each vector achieved in the absence of PIs.3 
Further analysis in vitro using bortezomib (see Supplementary 
Figure S1) demonstrated a tenfold increase of fluorescence on a 
single-strand wild-type size AAV2.GFP vector.
With respect to mechanism(s) that might explain the pro-
portionately greater increase in expression by combining PI with 
oversized transgenes, as compared to wild-type size transgenes, 
it should be noted that proteasomes are present in both the 
 cytoplasm and the nucleus. Although we demonstrate that nuclear 
accumulation is enhanced by bortezomib, it is possible that the 
relative enhancement of large transgene expression by PI may 
involve additional processes that occur in the nuclear compart-
ment. For example, we have recently reported that AAV2 virions 
enter the nucleus and accumulate in the nucleolus after infec-
tion, whereas empty particles are excluded from nuclear entry.27 
The virions that accumulate at the nucleolus retain infectivity. 
Furthermore, PIs potentiate nucleolar accumulation, as demon-
strated using AAV carrying wild-type size sequences. Nuclear 
trafficking, nuclear accumulation, and subsequent mobilization 
of the nucleolar fraction have not been studied using oversized 
AAV vectors, especially with regards to the relative effect of a PI 
on these mechanisms. More importantly, three papers recently 
described rigorous analysis of large genome encapsidation in AAV 
capsid. These studies independently demonstrated the propensity 
of AAV to package genomes efficiently within the range of 106% 
of wild-type size.22–24 Fragmented vector genomes were encapsi-
dated from transgenes above this size range (i.e., cFVIII-5.6 kb). 
Similar observations have been documented for other viruses 
(e.g., adenovirus packages between 88 and 105% of wild type) sug-
gesting a “head-full” packaging mechanism governing viral DNA 
genome size. It is hypothesized that full-length protein expressed 
from these vectors results from “intracellular reassembly of partial 
gene fragments.” It remains to be seen whether PIs facilitate a step 
in this newly hypothesized process of vector-fragmented genomes 
reassembly,25 but it is tempting to speculate that concentration of 
virion genomes in nuclear compartments after PI treatment (as 
previously described by Johnson et al.27) would potentiate this 
possibility.
Proteasome inhibition and impact on AAV vectors carrying 
a variety of different genome configurations should lead to better 
understanding of how to exploit pharmaceuticals as adjuvants to 
table 3 summary of hemophilia A dogs undergoing AAV-mediated gene therapy with proteasome inhibitor
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Cindy F 27 days AAV8 0.5 26 1 (4%) 9 12/18 months 0 Fatal bleeding
Mike M 22 days AAV8 1.0 26 4 (15.4%) 9 16/25 months 0 Fatal bleeding
Boober M 23 days AAV8 ND 18 0 (0%) NA 11/10 months 0 Alive
Carl M 25 days AAV8+bortezomib 3.1 34 20 (58.8%) 0 1/32.5 months 0 Alive
Greg M 25 days AAV8+bortezomib/
Dex
3.8 34 20 (58.8%) 0 2/32.5 months 0 Alive
Sprocket F 23 days AAV8+bortezomib ND 20 4 (20%) NA 2/11 months 0 Alive
Marjorie F 23 days AAV8+bortezomib/
Dex
2.2 20 8 (40%) NA 0/11 months 0 Alive
Denver M No treatment NA NA 10/22 months NA Alive
Bass M No treatment NA NA 13/22 months NA Alive
Gator M No treatment NA NA 10/22 months NA Alive
Abbreviations: BIU, Bethesda units; Dex, with dexamethasone; NA, not applicable; ND, not detected; WBCT, whole blood clotting time.
Normal value of 6–10 minutes for WBCT. WBCT is expressed as number of measurements in normal range in the total measurements.
aAge at vector administration.
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increase the action of gene vectors in “combination therapy.” For 
example, when characterizing AAV vectors having either a con-
ventional single-strand (ssAAV) or a self-complementing genome 
structure (scAAV), we observed an increase in the percentage of 
cells expressing transgene after AAV2.GFP transduction and bort-
ezomib coadministration (see Supplementary Materials and 
Methods and Supplementary Figure S1). In vitro, the amount of 
fluorescence from the population of successfully transduced cells 
was augmented to an even greater degree (from a mean fluores-
cence index of 75–890, Supplementary Figure S1) than the aug-
mentation we observed in vivo using ssAAV with WT-size FIX 
genome. The bortezomib in vitro augmentation of expression from 
a self-complementing vector was almost identical to that seen with 
ssAAV suggesting a common pathway regardless of vector template 
conformation. Interestingly, our scAAV in vitro analyses are consis-
tent with the report by Nathwani et al. who documented an increase 
in expression of factor IX mediated by bortezomib when coadmin-
istered with a self-complementary AAV8.FIX vector.28 Although 
there appear to be additional factors at play when augmenting 
oversized vector genomes compared to single-stranded and self-
complementary AAV templates, we were able in vitro to extend 
the effect of bortezomib enhancement to lentiviral vectors (see 
Supplementary Figure S1), suggesting that this drug augmenta-
tion may have universal application with respect to viral vector gene 
transfer even though it may be working by multiple mechanisms.
“combination therapy” and clinical trials
Preclinical licensure studies and extensive clinical experience 
with bortezomib and dexamethasone exist to suggest consider-
ing the use of these drugs in combination with gene delivery to 
augment persistent gene expression. It is important to recognize 
that both drugs have significant side effect profiles, although for 
each drug many of the side effects arise in a cumulative fashion, 
as each drug is usually dosed repeatedly in clinical applications. 
Single-dose dexamethasone may have potent short-term anti-
inflammatory effects, and is at times given clinically to achieve 
anti-inflammatory effect even in the presence of bacterial or viral 
infectious processes. Clinically, cumulative bortezomib (generally 
given in multiple courses, each course consisting of 2 weeks of 
twice-weekly dosing) is associated with peripheral neuropathy, 
cytopenias (thrombocytopenia, neutropenia) and other toxicities, 
which may be severe. Single-dose toxicity in animal preclinical 
testing was minimal at the doses used in our study and approved 
for drug licensure. Nevertheless, the drug has a narrow margin of 
safety and liver failure as an idiosyncratic reaction can be seen at 
any time during treatment including with the first dose. Studies 
are ongoing in our laboratories to determine whether using lower 
doses of the single coadministration of bortezomib will also aug-
ment transduction while increasing the safety of our single adju-
vant dose approach.
Undoubtedly, PIs can affect a multitude of cellular processes, 
and further studies are required to dissect the significant differ-
ences between oversized and wild-type AAV transgene cassettes. 
The specific application of PIs to enhance the delivery of trans-
genes that exceed the size of the wild-type AAV genome has not 
been demonstrated previously in vivo. Furthermore, until these 
studies, phenotypic improvement achieved by coadministration 
of a PI with AAV vector has not been demonstrated in any large 
animal model using AAV vectors. Nevertheless, the clear augmen-
tation of AAV8-mediated expression of the large FVIII transgene 
that we report here using bortezomib, along with previous stud-
ies in which PI augment AAV1 and AAV5 vector transduction,3,26 
suggest that PIs may enhance the efficiency of AAV gene delivery 
in a wide variety of contexts.
In conclusion, we demonstrate in the context of multiple AAV 
serotypes, and in small and large animal disease models the ben-
eficial safety profile and efficacy of the PI bortezomib to enhance 
AAV-mediated expression of large therapeutic genes in combi-
nation therapy. These findings warrant further investigation of 
mechanisms for improved vector transduction and establish pre-
clinical parameters that support eventual testing in phase I clinical 
application.
MAterIAls And Methods
AAV vectors, HIV-based vectors, and additional drugs. The factor VIII 
expression vector used in these studies has been described previously by one 
of the authors (R.S.).6 The vector contains a canine B domain deleted (BDD) 
FVIII (cFVIII) cDNA driven by a synthetically derived short liver-specific 
promoter/enhancer, followed by a chimeric intron (IGBP/enh/intron). The 
factor IX vector has been described previously and contains a 4.2 kb expres-
sion cassette including the hFIX cDNA (1.4 kb) under transcriptional con-
trol of CMV enhancer/chicken β-actin promoter (rAAV-CBA-hFIX)30 All 
vectors were produced and titered at the UNC Virus Vector Core Facility 
as described previously,43 including single-strand and self-complementary 
AAV2 encoding green fluorescent protein (GFP), driven by CMV pro-
moter (total size about 1.5 kb); firefly luciferase encapsidated with AAV8 
capsid; driven by CBA promoter; and AAV2 and AAV8 expressing human 
factor IX (hFIX). The HIV-based, integrase-deficient vector was generated 
by the transient transfection method as previously described.44 Bortezomib 
(Millennium Pharmaceuticals, Cambridge, MA) was diluted in phosphate-
buffered saline for injection. MG-132 (Calbiochem, La Jolla, CA) was dis-
solved with 70% ethanol to 20 mmol/l as stock solution. Dexamethasone 
was purchased from Sicor Pharmaceuticals, Irvine, CA.
Animal care and studies
Mice: FVIII-deficient mice (FVIII−/−) with a targeted deletion of exon 16 
of the FVIIII gene45 were generously supplied by H.H. Kazazian Jr.’s 
laboratory (University of Pennsylvania, Philadelphia, PA). C57Bl/6 
FIX−/− mice have a targeted deletion of the promoter through the third 
exon of the FIX gene.46 FVIII−/− and FIX−/− mice were bred in house. 
Wild-type C57Bl/6 mice for luciferase vector delivery at 7–8 weeks of 
age were purchased from the Jackson Laboratory (Bar Harbor, ME). 
Hemophilic mice were anesthetized using 2.5% Avertin for all procedures. 
All plasma samples were collected from the retro-orbital plexus into 3.2% 
sodium citrate and stored at −80 °C. Retro-orbital blood collection and 
bioluminescence imaging were performed under isoflurane anesthesia. 
All studies in mice were approved by the Institutional Animal Care and 
Use Committee of the University of North Carolina at Chapel Hill.
FIX−/− mice received portal vein injection of 3 × 1010 gc/animal 
AAV2.hFIX or AAV8.hFIX vector in a total volume of 200 µl with or 
without a single dose of bortezomib (0.5 mg/kg) at the time of AAV 
delivery. FVIII−/− mice underwent portal vein injection of 3 × 1010 gc/
mouse AAV2.cFVIII or AAV8.cFVIII, along with bortezomib or MG-132 
(0.5 mg/kg body weight), as well as mice received a single dose of 1 mg/kg 
of recombinant human factor VIIa (NovoSeven, Novo Nordisk, Bagsværd, 
Denmark) to support perioperative hemostasis. To avoid anticipated 
antibody-mediated immune responses to the canine FVIII transgene, all 
FVIII−/− mice received cyclophosphamide (Sigma Aldrich, St Louis, MO) 
injected intraperitoneally in three doses of 100 µg each on days −3, 0, and 
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+3, as previously described.6 C57Bl/6 mice received 1011 vector genomes/
mouse AAV8 expressing firefly luciferase under transcriptional control of 
CMV enhancer/chicken β-actin promoter via tail vein; groups receiving 
dexamethasone therapy were treated with 0.2 mg/animal intraperitoneally 
1–2 hours prior to AAV delivery.
Animal care and studies
Hemophilia A dogs: The hemophilia A dogs were mixed-breed dogs from 
the hemophilia A colony initially housed at the Scott-Ritchey Research 
Center, Auburn University but now at the UAB Medical School. All 
studies in dogs were approved by the Institutional Animal Care and 
Use Committees of Auburn University and the University of Alabama, 
Birmingham, AL. All animals were housed in facilities that are AAALAC 
accredited. Treated dogs were males (n = 4) or females (n = 3) with 
severe hemophilia A. All seven dogs were administered AAV8.cFVIII by 
mesenteric vein administration 3–4 weeks following birth.47 Four dogs 
(two females/two males) were also administered bortezomib (1.3 mg/m2) 
at the time of vector administration. One male and one female dog were 
administered i.v. dexamethasone (1.0 mg/kg) at the time of vector and 
bortezomib administration.
Coagulation factor VIII and factor IX activity assays and canine  factor 
VIII Bethesda inhibitor antibody assay in mice. Canine FVIII activity 
in mouse plasma was measured by the Coatest SP4 kit (Chromogenix, 
DiPharma, West Chester, OH) following the manufacturer’s instruc-
tion with modification. Normal canine plasma (regarded as 100 percent 
 activity = 1 IU/ml) was serially diluted into FVIII−/− pooled mouse plasma 
to generate the standard curve. Neutralizing antibodies to canine FVIII 
in mouse plasma were measured by the Bethesda assay using a STart 4 
Coagulation Analyzer (Diagnostica Stago, Asnières, France) as described.48 
Human factor IX was measured based on one-stage factor IX activity assay 
(FIX-specific aPTT) as previously described, using a STart 4 Coagulation 
Analyzer.49
FVIII activity, coagulation, and Bethesda assays in dogs. Blood samples 
were obtained from normal controls, untreated FVIII controls, and treated 
hemophilia A dogs as described.47 WBCT, FVIII activity, and Bethesda 
titer were measured as previously reported. The WBCT assay was termi-
nated at 20 minutes if a clot had not formed.
Preparation of hepatic cell nuclear and cytoplasmic extract. Nuclear and 
cytoplasmic fractions were isolated as described50 with slight modifica-
tion. Mouse livers were perfused with phosphate-buffered saline, minced 
on ice and homogenized [buffer: 250 mmol/l sucrose, 50 mmol/l Tris-HCl 
(pH 7.5), 25 mmol/l KCl, 5 mmol/l MgCl2, 0.5% NP-40, 1 mmol/l phenyl-
methylsulfonyl fluoride], using a Dounce homogenizer. Nuclei and other 
organelles were collected by centrifugation for 10 minutes at 3,000 rpm in 
a Sorvall clinical centrifuge. The supernatant was filtered using a 40 µm 
pore-size filter and used as the cytoplasm. The multilayered pellet was pro-
cessed further into nuclear extract dissolved into distilled water.
suPPleMentArY MAterIAl
Figure S1. Proteasome inhibitor increases expression of AAV-2 vectors 
in vitro.
Table S1. Effect of dexamethasone coadministration with AAV8.lu-
ciferase upon transgene expression outside of liver.
Materials and Methods.
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